Last reviewed · How we verify

low molecular weight heparin, 5-FU

Shahid Beheshti University of Medical Sciences · Phase 3 active Small molecule

low molecular weight heparin, 5-FU is a Anticoagulant Small molecule drug developed by Shahid Beheshti University of Medical Sciences. It is currently in Phase 3 development for Prophylaxis and treatment of deep vein thrombosis and pulmonary embolism, Prophylaxis and treatment of atrial fibrillation for stroke prevention.

Low molecular weight heparin works by inhibiting Factor Xa and thrombin, preventing blood clot formation.

Low molecular weight heparin works by inhibiting Factor Xa and thrombin, preventing blood clot formation. Used for Prophylaxis and treatment of deep vein thrombosis and pulmonary embolism, Prophylaxis and treatment of atrial fibrillation for stroke prevention.

At a glance

Generic namelow molecular weight heparin, 5-FU
SponsorShahid Beheshti University of Medical Sciences
Drug classAnticoagulant
TargetFactor Xa, Thrombin
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

Low molecular weight heparin is a type of anticoagulant that selectively inhibits Factor Xa and thrombin, which are key enzymes in the coagulation cascade. This inhibition prevents the formation of blood clots, which can cause serious health problems such as deep vein thrombosis and pulmonary embolism.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about low molecular weight heparin, 5-FU

What is low molecular weight heparin, 5-FU?

low molecular weight heparin, 5-FU is a Anticoagulant drug developed by Shahid Beheshti University of Medical Sciences, indicated for Prophylaxis and treatment of deep vein thrombosis and pulmonary embolism, Prophylaxis and treatment of atrial fibrillation for stroke prevention.

How does low molecular weight heparin, 5-FU work?

Low molecular weight heparin works by inhibiting Factor Xa and thrombin, preventing blood clot formation.

What is low molecular weight heparin, 5-FU used for?

low molecular weight heparin, 5-FU is indicated for Prophylaxis and treatment of deep vein thrombosis and pulmonary embolism, Prophylaxis and treatment of atrial fibrillation for stroke prevention.

Who makes low molecular weight heparin, 5-FU?

low molecular weight heparin, 5-FU is developed by Shahid Beheshti University of Medical Sciences (see full Shahid Beheshti University of Medical Sciences pipeline at /company/shahid-beheshti-university-of-medical-sciences).

What drug class is low molecular weight heparin, 5-FU in?

low molecular weight heparin, 5-FU belongs to the Anticoagulant class. See all Anticoagulant drugs at /class/anticoagulant.

What development phase is low molecular weight heparin, 5-FU in?

low molecular weight heparin, 5-FU is in Phase 3.

What are the side effects of low molecular weight heparin, 5-FU?

Common side effects of low molecular weight heparin, 5-FU include Bleeding, Hypersensitivity reactions, Thrombocytopenia.

What does low molecular weight heparin, 5-FU target?

low molecular weight heparin, 5-FU targets Factor Xa, Thrombin and is a Anticoagulant.

Related